Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Palmitoyl-dipeptide-6

Palmitoyl Dipeptide-6 Diaminohydroxybutyrate, Pal-Lys-Val-Dab

Quick Stats
Studies 98
Trials 0
2026 pubmed

Tumor mRNA-lipid nanoparticles via chimeric nanobody-lipid co-assembly.

Zhu. Chuandong C; Wang. Jing J; Rahman. Md Mofizur MM; Zhang. Yun Y; Wang. Lixue L; Wan. Yuan Y

Key Findings

  • A one‑step, PEG‑free method to assemble HER2‑targeted mRNA‑LNPs using palmitoylated nanobodies.
  • The resulting particles show improved tumor targeting, longer tumor retention, and greater tumor shrinkage in mouse models.
  • Strong immune activation against spike‑protein‑expressing tumor cells was observed in vitro and in vivo.

Practical Outcomes

  • For the biohacker community, this study offers no direct, actionable protocol or dosage guidance related to palmitoyl‑dipeptide‑6. It is a specialized cancer‑immunotherapy technique that requires advanced molecular biology tools and is not applicable to everyday health‑optimization practices.

Summary

The paper describes a new way to make cancer‑targeted mRNA nanoparticles by attaching a palmitoylated nanobody to the particle surface, avoiding PEG. It shows better delivery to HER2‑positive tumors and stronger anti‑tumor immune responses in mice, but it does not involve the skin‑care peptide palmitoyl‑dipeptide‑6 or give any advice that biohackers could use.

Abstract

<b>Background:</b> Targeted mRNA-lipid nanoparticles (LNP) show great potential for cancer immunotherapy by delivering neoantigen-encoding messages to tumor cells, prompting immune responses against tumors. However, the challenges of inefficient production of targeting ligand-grafted LNPs and the immunogenic effects of polyethylene glycol (PEG) hinder their therapeutic effectiveness. <b>Methods:</b> We introduced a simplified, one-step technique for creating PEG-free, human epidermal growth factor receptor 2 (HER2)-targeted mRNA-LNPs. This method incorporates self-assembled palmitoylated nanobodies (pNB), lipids, and mRNA that encode spike proteins (SP). We engineered cells to produce pNB, which were then mixed with lipids and mRNA at various ratios. Through hydrophobic interactions between the lipid tails and the palmitoyl groups, we assembled tumor-targeting mRNA-LNPs. We optimized both the lipid components and the quantity of pNB, and determined the optimal formulation based on a series of physicochemical characterizations of the LNP as well as in vitro cel assays. Building on this, we further conducted in vitro cytotoxicity assays targeting SP-expressing cells, followed by in vivo immune killing experiments. <b>Results:</b> In vitro, SP-expressing tumor cells triggered strong immune responses and effective tumor cell destruction. Additionally, these pNB-LNPs demonstrated improved tumor-specific delivery, extended tumor retention, and considerable tumor volume reduction in vivo. <b>Conclusion:</b> This streamlined, PEG-free LNPs platform that utilizes pre-existing immunity presents a flexible strategy for targeted cancer immunotherapy and applications in infectious diseases.

Study Information

Provider

pubmed

Year

2026

Date

2026-01-01T00:00:00.000Z

DOI

10.7150/thno.123633

References

38